Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND: SALI-10 Probiotic to Mitigate Dental Toxicity Post-Radiation in Head and Neck Cancer
NCT07883005Phase 3Not yet recruiting
- Sponsor
- University Health Network
- Start
- Nov 2026
- Primary completion
- Nov 2031
- Countries
- 1
01
Overview
Phase 3, randomised trial of SALI-10 in dental caries and osteoradionecrosis (ORN) (2 arms), sponsored by University Health Network. Primary endpoint: Incidence of Major Adverse Dental Events (MADE) at 2 years. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SALI-10
03
Conditions
dental cariesosteoradionecrosis (ORN)
Beyond the preview
Go deeper on NCT07883005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883005.